Dihydroergotamine methanesulfonate en es it fr

Dihydroergotamine methanesulfonate Brand names, Dihydroergotamine methanesulfonate Analogs

Dihydroergotamine methanesulfonate Brand Names Mixture

  • No information avaliable

Dihydroergotamine methanesulfonate Chemical_Formula

C33H37N5O5

Dihydroergotamine methanesulfonate RX_link

http://www.rxlist.com/cgi/generic2/dihyergmes.htm

Dihydroergotamine methanesulfonate fda sheet

Dihydroergotamine_methanesulfonate FDA

Dihydroergotamine methanesulfonate msds (material safety sheet)

Dihydroergotamine_methanesulfonate MSDS

Dihydroergotamine methanesulfonate Synthesis Reference

No information avaliable

Dihydroergotamine methanesulfonate Molecular Weight

583.678 g/mol

Dihydroergotamine methanesulfonate Melting Point

No information avaliable

Dihydroergotamine methanesulfonate H2O Solubility

No information avaliable

Dihydroergotamine methanesulfonate State

Solid

Dihydroergotamine methanesulfonate LogP

No information avaliable

Dihydroergotamine methanesulfonate Dosage Forms

Liquid

Dihydroergotamine methanesulfonate Indication

For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.

Dihydroergotamine methanesulfonate Pharmacology

Dihydroergotamine is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. Dihydroergotamine binds with high affinity to 5-HT1Da and 5-HT1Db receptors. It also binds with high affinity to serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, noradrenaline a2A, a2B and a receptors, and dopamine D2L and D3 receptors. The therapeutic activity of Dihydroergotamine in migraine is generally attributed to the agonist effect at 5-HT1D receptors.

Dihydroergotamine methanesulfonate Absorption

Interpatient variable and may be dependent on the administration technique

Dihydroergotamine methanesulfonate side effects and Toxicity

Side effects include abdominal pain, abnormal speech, coma, confusion, convulsions, hallucinations, increase and/or decrease in blood pressure, nausea, numbness, tingling, pain, and a bluish color of your fingersand toes, slowed breathing, vomiting

Dihydroergotamine methanesulfonate Patient Information

PATIENT INFORMATIOn

Follow the link below to get detailed information before taking D.H.E. 45 (dihydroergotamine mesylate) Injection.

http://www.rxlist.com/cgi/generic2/dihyergmes_pi.htm

Dihydroergotamine methanesulfonate Organisms Affected

Humans and other mammals